首页> 外文期刊>Journal of Medicinal Chemistry >Design, Synthesis, and Biological Evaluation of New 8-Heterocyclic Xanthine Derivatives as Highly Potent and Selective Human A_(2B) Adenosine Receptor Antagonists
【24h】

Design, Synthesis, and Biological Evaluation of New 8-Heterocyclic Xanthine Derivatives as Highly Potent and Selective Human A_(2B) Adenosine Receptor Antagonists

机译:新型8杂环黄嘌呤衍生物作为高强度和选择性人类A_(2B)腺苷受体拮抗剂的设计,合成和生物学评估

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Here we report the synthesis of 8-heterocycle-substituted xanthines as potent and selective A_(2B) adenosine receptor antagonists. The structure-activity relationships (SAR) of the xanthines synthesized in binding to recombinant human A_(2B) adenosine receptors (ARs) in HEK-293 cells (HEK-A_(2B)) and at other AR subtypes were explored. The synthesized compounds showed A_(2B) adenosine receptor affinity in the nanomolar range and good levels of selectivity evaluated in radioligand binding assays at human (h) A_1, A_(2A), A_(2B), and A_3 ARs. We introduced several heterocycles, such as pyrazole, isoxazole, pyridine, and pyridazine, at the 8-position of the xanthine nucleus and we have also investigated different spacers (substituted acetamide, oxyacetamide, and urea moieties) on the heterocycle introduced. Various groups at the 3- and 4-positions of phenylacetamide moiety were studied. This study allowed us to identify the derivatives 2-(3,4-dimethoxyphenyl)-N-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl]acetamide (29b, MRE2028F20) [K_i(hA_(2B)) = 38 nM, K_i(hA_1,hA_(2A),hA_3) > 1000 nM], N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]acetamide (62b, MRE2029F20) [K_i(hA_(2B)) = 5.5 nM, K_i(hA_1,hA_(2A),hA_3) > 1000 nM], and N-(3,4-dimethoxyphenyl)-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]acetamide (72b, MRE2030F20) [K_i(hA_(2B) = 12 nM, K_i(hA_1,hA_(2A), hA_3) > 1000 nM], which showed high affinity at the A_(2B) receptor subtype and very good selectivity vs the other ARs. Substitution of the acetamide with an urea moiety afforded bioisosteric xanthines with good affinity and selectivity comparable to the acetamide derivatives. Substitution at the para-position of a 4-benzyloxy group of the phenylacetamido chain enhanced affinity at the A2B receptor [compound 30b (K_i(hA_(2B)) = 13 nM) vs compound 21b (K_i(hA_(2B) = 56 nM)] but did not favor selectivity. The derivatives with higher affinity at human A_(2B) AR proved to be antagonists, in the cyclic AMP assay, capable of inhibiting the stimulatory effect of NECA (100 nM) with IC50 values in the nanomolar range, a trend similar to that observed in the binding assay (62b, IC_(50) = 38 nM; 72b, IC_(50) = 46 nM). In conclusion, the 8-pyrazolo-1,3-dipropyl-1H-purine-2,6-dione derivatives described herein represent a new family of selective antagonists for the adenosine A_(2B) receptor.
机译:在这里,我们报告8杂环取代的黄嘌呤作为有效和选择性A_(2B)腺苷受体拮抗剂的合成。探索了黄嘌呤与HEK-293细胞(HEK-A_(2B))和其他AR亚型中的重组人A_(2B)腺苷受体(AR)结合而合成的结构-活性关系(SAR)。合成的化合物在纳摩尔范围内显示A_(2B)腺苷受体亲和力,并且在人(h)A_1,A_(2A),A_(2B)和A_3 AR的放射性配体结合测定中评估了良好的选择性水平。我们在黄嘌呤核的8位引入了几个杂环,例如吡唑,异恶唑,吡啶和哒嗪,我们还研究了所引入杂环上的不同间隔基(取代的乙酰胺,氧乙酰胺和尿素部分)。研究了苯基乙酰胺部分3和4位的各种基团。这项研究使我们能够确定衍生物2-(3,4-二甲氧基苯基)-N- [5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin- 8-yl)-1-甲基-1H-吡唑-3-基]乙酰胺(29b,MRE2028F20)[K_i(hA_(2B))= 38 nM,K_i(hA_1,hA_(2A),hA_3)> 1000 nM] ,N-苯并[1,3]二氧杂-5-基-2- [5-(2,6-二氧杂-1,3-二丙基-2,3,6,7-四氢-1H-嘌呤-8-基)-1-甲基-1H-吡唑-3-基氧基]乙酰胺(62b,MRE2029F20)[K_i(hA_(2B))= 5.5 nM,K_i(hA_1,hA_(2A),hA_3)> 1000 nM]和N -(3,4-二甲氧基苯基)-2- [5-(2,6-二氧代-1,3-二丙基-2,3,6,7-四氢-1H-嘌呤-8-基)-1-甲基- 1H-吡唑-3-基氧基]乙酰胺(72b,MRE2030F20)[K_i(hA_(2B)= 12 nM,K_i(hA_1,hA_(2A),hA_3)> 1000 nM],对A_(2B受体亚型和相对于其他AR的很好的选择性。用尿素部分取代乙酰胺可提供生物等效的黄嘌呤,与乙酰胺衍生物相比具有良好的亲和力和选择性。在苯乙酰胺基链的4-苄氧基对位取代在A2B受体上的亲和力增强[化合物30b(K_i(hA_(2B))= 13 nM)与化合物21b(K_i(hA_(2B)= 56 nM)],但不利于选择性。在循环AMP分析中,对人A_(2B)AR具有较高亲和力的衍生物被证明是拮抗剂,能够抑制纳卡(100 nM)的刺激作用,IC50值在纳摩尔范围内,这种趋势类似于在纳摩尔浓度下观察到的趋势。结合测定(62b,IC_(50)= 38 nM; 72b,IC_(50)= 46 nM)。总之,本文所述的8-吡唑并-1,3-二丙基-1H-嘌呤-2,6-二酮衍生物代表腺苷A_(2B)受体的新的选择性拮抗剂家族。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号